Catalyst Pharmaceuticals Inc (CPRX) - News Archive

In a notable development for the pharmaceutical industry, Catalyst Pharmaceuticals Inc. recently announced a settlement with Lupin Pharmaceuticals concerning the patent litigation of FIRDAPSE (amifampridine). This settl...

Catalyst Pharmaceuticals Inc. recently celebrated a significant milestone with its sub-licensee DyDo Pharma s successful launch of FIRDAPSE in Japan. This introduction marks a crucial step for Catalyst as it continues t...

Catalyst Pharmaceuticals: A Paragon of Growth Through Operational Prowess and Commercial Acumen Catalyst Pharmaceuticals has garnered significant recognition on the prestigious Deloitte Technology Fast 500 list for 2024...

Catalyst Pharmaceuticals Inc., a renowned biopharmaceutical company specializing in developing and commercializing groundbreaking medicines for rare and challenging diseases, recently announced a significant milestone i...

Catalyst Pharmaceuticals to Showcase Innovations at Jefferies Global Healthcare Conference 2024CORAL GABLES, Fla., May 28, 2024 - Catalyst Pharmaceuticals, Inc. (Catalyst or Company) (Nasdaq: CPRX), a leading biopharmac...

In recent developments, Catalyst Pharmaceuticals has announced the publication of Santhera Pharmaceuticals VISION-DMD study results in the esteemed peer-reviewed journal, Neurology. The study elucidated the 48-week trea...

Catalyst Pharmaceuticals, Inc. Successfully Closes Public Offering, Intensifying Investor InterestCoral Gables, Florida - Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced the completion of its underwritten public...

CORAL GABLES, Fla., Jan. 05, 2024 - Catalyst Pharmaceuticals, Inc. (Catalyst or the Company) (Nasdaq: CPRX) has made a significant move towards strengthening its financial position by announcing the pricing of an underw...

Catalyst Pharmaceuticals Inc. (Catalyst), a leading biopharmaceutical company specializing in rare disease treatments, has recently announced its plans to commence an underwritten public offering of $150,000,000 of its...

Florida-based biopharmaceutical firm Catalyst Pharmaceuticals has taken significant steps to introduce its novel treatment for Lambert Eaton myasthenic syndrome (LEMS) into the Japanese market. Catalyst s partner, DyDo...

Expanding Catalyst Pharmaceuticals Patent Portfolio: A Major Boost for FIRDAPSE In an exciting development for the pharmaceutical industry, Catalyst Pharmaceuticals, a biopharmaceutical company focused on rare neuromusc...